| pubmed-article:18759760 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18759760 | lifeskim:mentions | umls-concept:C0231335 | lld:lifeskim |
| pubmed-article:18759760 | lifeskim:mentions | umls-concept:C0023470 | lld:lifeskim |
| pubmed-article:18759760 | lifeskim:mentions | umls-concept:C0010711 | lld:lifeskim |
| pubmed-article:18759760 | lifeskim:mentions | umls-concept:C1533699 | lld:lifeskim |
| pubmed-article:18759760 | lifeskim:mentions | umls-concept:C1979893 | lld:lifeskim |
| pubmed-article:18759760 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:18759760 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:18759760 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:18759760 | pubmed:dateCreated | 2008-11-6 | lld:pubmed |
| pubmed-article:18759760 | pubmed:abstractText | Gemtuzumab ozogamicin (GO) monotherapy is reported to yield a 20-30% response rate in advanced acute myeloid leukaemia (AML). This study examined the efficacy and tolerability of GO combined with cytarabine (GOCYT) in children with refractory/relapsed CD33(+) AML. Seventeen children received GO 3 mg/m(2) on days 1, 4 and 7 plus cytarabine 100 mg/m(2)/d for 7 d on a compassionate-use basis. Seven patients then received GO-based consolidation. At the outset of GOCYT, two patients were refractory; eight patients were in refractory first relapse; six patients had relapsed after stem cell transplantation (SCT); and one patient [del(5q) therapy-related AML (t-AML)] had not yet been treated. Mean follow-up was 17 months (8-33 months). Ten responses were obtained after GOCYT induction, including complete remission (CR) or CR without complete recovery of platelets (CRp) in six patients (35%). The responses improved in three children who received GOCYT consolidation, increasing the CR + CRp rate to 53%. SCT was subsequently performed in eight responders. Grade 3-4 adverse events consisted of haematological disorders (n = 17, 100%) and documented infections (n = 5, 29%). No cases of sinusoidal obstructive syndrome occurred. Three patients were alive at the cut-off date for this analysis, all of whom had responded to GOCYT. GOCYT combination therapy yielded a high response rate (53%) and showed acceptable toxicity in heavily pretreated children with refractory/relapsed AML. These results warrant a larger prospective study. | lld:pubmed |
| pubmed-article:18759760 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18759760 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18759760 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18759760 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18759760 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18759760 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18759760 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18759760 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18759760 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18759760 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18759760 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:18759760 | pubmed:issn | 1365-2141 | lld:pubmed |
| pubmed-article:18759760 | pubmed:author | pubmed-author:ChevretSylvie... | lld:pubmed |
| pubmed-article:18759760 | pubmed:author | pubmed-author:LeblancThierr... | lld:pubmed |
| pubmed-article:18759760 | pubmed:author | pubmed-author:NelkenBrigitt... | lld:pubmed |
| pubmed-article:18759760 | pubmed:author | pubmed-author:DalleJean-Hug... | lld:pubmed |
| pubmed-article:18759760 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:18759760 | pubmed:author | pubmed-author:BaruchelAndré... | lld:pubmed |
| pubmed-article:18759760 | pubmed:author | pubmed-author:BrunoBénédict... | lld:pubmed |
| pubmed-article:18759760 | pubmed:author | pubmed-author:BrethonBenoit... | lld:pubmed |
| pubmed-article:18759760 | pubmed:author | pubmed-author:BertrandYvesY | lld:pubmed |
| pubmed-article:18759760 | pubmed:author | pubmed-author:BoutardPatric... | lld:pubmed |
| pubmed-article:18759760 | pubmed:author | pubmed-author:YakoubenKarim... | lld:pubmed |
| pubmed-article:18759760 | pubmed:author | pubmed-author:OudotCaroline... | lld:pubmed |
| pubmed-article:18759760 | pubmed:author | pubmed-author:JéromeCécileC | lld:pubmed |
| pubmed-article:18759760 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18759760 | pubmed:volume | 143 | lld:pubmed |
| pubmed-article:18759760 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18759760 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18759760 | pubmed:pagination | 541-7 | lld:pubmed |
| pubmed-article:18759760 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:meshHeading | pubmed-meshheading:18759760... | lld:pubmed |
| pubmed-article:18759760 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18759760 | pubmed:articleTitle | Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. | lld:pubmed |
| pubmed-article:18759760 | pubmed:affiliation | Hématologie Pédiatrique, Hôpital Saint-Louis, APHP, Paris, France. benoit.brethon@sls.aphp.fr | lld:pubmed |
| pubmed-article:18759760 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18759760 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18759760 | lld:pubmed |
